Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.

Zhao CY, Greenstein JL, Winslow RL.

J Mol Cell Cardiol. 2016 Feb;91:215-27. doi: 10.1016/j.yjmcc.2016.01.004. Epub 2016 Jan 7.

PMID:
26773602
2.

Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Zhao CY, Greenstein JL, Winslow RL.

J Mol Cell Cardiol. 2015 Nov;88:29-38. doi: 10.1016/j.yjmcc.2015.09.011. Epub 2015 Sep 23.

PMID:
26388264
3.

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications.

Corinaldesi C, Di Luigi L, Lenzi A, Crescioli C.

J Endocrinol Invest. 2016 Feb;39(2):143-51. doi: 10.1007/s40618-015-0340-5. Epub 2015 Jun 28.

4.

Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury.

Chung YW, Lagranha C, Chen Y, Sun J, Tong G, Hockman SC, Ahmad F, Esfahani SG, Bae DH, Polidovitch N, Wu J, Rhee DK, Lee BS, Gucek M, Daniels MP, Brantner CA, Backx PH, Murphy E, Manganiello VC.

Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):E2253-62. doi: 10.1073/pnas.1416230112. Epub 2015 Apr 15.

5.

Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2.

Ahmad F, Shen W, Vandeput F, Szabo-Fresnais N, Krall J, Degerman E, Goetz F, Klussmann E, Movsesian M, Manganiello V.

J Biol Chem. 2015 Mar 13;290(11):6763-76. doi: 10.1074/jbc.M115.638585. Epub 2015 Jan 15.

6.

Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D, Manganiello V.

Oral Dis. 2015 Jan;21(1):e25-50. doi: 10.1111/odi.12275. Epub 2014 Sep 12.

7.

β-adrenergic receptor-dependent alterations in murine cardiac transcript expression are differentially regulated by gefitinib in vivo.

Talarico JA, Carter RL, Grisanti LA, Yu JE, Repas AA, Tilley DG.

PLoS One. 2014 Jun 5;9(6):e99195. doi: 10.1371/journal.pone.0099195. eCollection 2014.

8.

Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms.

Vandeput F, Szabo-Fresnais N, Ahmad F, Kho C, Lee A, Krall J, Dunlop A, Hazel MW, Wohlschlegel JA, Hajjar RJ, Houslay MD, Manganiello VC, Movsesian MA.

Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19778-83. doi: 10.1073/pnas.1305427110. Epub 2013 Nov 18.

9.

Therapeutic potential of PDE modulation in treating heart disease.

Knight W, Yan C.

Future Med Chem. 2013 Sep;5(14):1607-20. doi: 10.4155/fmc.13.127. Review.

10.

PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients.

Molenaar P, Christ T, Hussain RI, Engel A, Berk E, Gillette KT, Chen L, Galindo-Tovar A, Krobert KA, Ravens U, Levy FO, Kaumann AJ.

Br J Pharmacol. 2013 Jun;169(3):528-38. doi: 10.1111/bph.12167.

11.

Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart.

Beca S, Ahmad F, Shen W, Liu J, Makary S, Polidovitch N, Sun J, Hockman S, Chung YW, Movsesian M, Murphy E, Manganiello V, Backx PH.

Circ Res. 2013 Jan 18;112(2):289-97. doi: 10.1161/CIRCRESAHA.111.300003. Epub 2012 Nov 19.

12.

Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.

Knight WE, Yan C.

Horm Metab Res. 2012 Sep;44(10):766-75. doi: 10.1055/s-0032-1321870. Epub 2012 Sep 5. Review.

13.

p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction.

Le NT, Takei Y, Shishido T, Woo CH, Chang E, Heo KS, Lee H, Lu Y, Morrell C, Oikawa M, McClain C, Wang X, Tournier C, Molina CA, Taunton J, Yan C, Fujiwara K, Patterson C, Yang J, Abe J.

Circ Res. 2012 Feb 17;110(4):536-50. doi: 10.1161/CIRCRESAHA.111.254730. Epub 2012 Jan 19.

14.

Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes.

Sassi Y, Abi-Gerges A, Fauconnier J, Mougenot N, Reiken S, Haghighi K, Kranias EG, Marks AR, Lacampagne A, Engelhardt S, Hatem SN, Lompre AM, Hulot JS.

FASEB J. 2012 Mar;26(3):1009-17. doi: 10.1096/fj.11-194027. Epub 2011 Nov 16.

15.

Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility.

Begum N, Shen W, Manganiello V.

Curr Opin Pharmacol. 2011 Dec;11(6):725-9. doi: 10.1016/j.coph.2011.10.006. Epub 2011 Nov 1. Review.

16.

PDE3 inhibition in dilated cardiomyopathy.

Movsesian M, Wever-Pinzon O, Vandeput F.

Curr Opin Pharmacol. 2011 Dec;11(6):707-13. doi: 10.1016/j.coph.2011.09.001. Epub 2011 Sep 28. Review.

18.

Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger.

Insel PA, Zhang L, Murray F, Yokouchi H, Zambon AC.

Acta Physiol (Oxf). 2012 Feb;204(2):277-87. doi: 10.1111/j.1748-1716.2011.02273.x. Epub 2011 May 26. Review.

19.

Phosphodiesterase 3A expression is modulated by nitric oxide in rat pulmonary artery smooth muscle cells.

Busch CJ, Graveline AR, Jiramongkolchai K, Liu H, Sanchez LS, Bloch KD.

J Physiol Pharmacol. 2010 Dec;61(6):663-9.

20.

Computational models reduce complexity and accelerate insight into cardiac signaling networks.

Yang JH, Saucerman JJ.

Circ Res. 2011 Jan 7;108(1):85-97. doi: 10.1161/CIRCRESAHA.110.223602. Review.

Items per page

Supplemental Content

Write to the Help Desk